Fesoterodine (L-mandelate)

Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB) [1][2].

Product Specifications

CAS Number

[1206695-46-6]

UNSPSC

12352005

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/fesoterodine-l-mandelate.html

Purity

99.00

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H](C(O)=O)C1=CC=CC=C1.O=C(C(C)C)OC2=CC=C(CO)C=C2[C@@H](C3=CC=CC=C3)CCN(C(C)C)C(C)C

Molecular Formula

C34H45NO6

Molecular Weight

563.72

References & Citations

[1]Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.|[2]Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats|[3]Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101 (8) :1036-42.|[4]Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9 (10) :1787-96.